Briacell Therapeutics’ Subsidiary, BriaPro, Files Patent Application For Immuno-Oncology Platform With Novel Multitargeting Agents
RefinitivBacaan kurang dari 1 minit
Briacell Therapeutics Corp BCT:
BRIACELL’S SUBSIDIARY, BRIAPRO, FILES PATENT APPLICATION FOR IMMUNO-ONCOLOGY PLATFORM WITH NOVEL MULTITARGETING AGENTS
Log masuk atau cipta satu akaun percuma selamanya untuk membaca berita ini